Allos Therapeutics' odds of FDA approval are high Print E-mail
By M.E.Garza   
Thursday, 03 September 2009 08:10

After announcing yesterday that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), Allos Therapeutics, Inc. (Nasdaq: ALTH) appears likely to get FDA approval for the drug.  

Needham & Company, LLC, a subsidiary of The Needham Group, Inc., thinks the terminology issued by the Advisory Committee suggests that the drug will be approved by the FDA on September 24. The firm thinks the company will obtain an ex-U.S. partnership in the longer time and it reiterates a Buy rating on the stock.

Needham & Company, LLC, a subsidiary of The Needham Group, Inc., is a nationally recognized investment banking and asset management firm focused solely on growth companies and their investors. Needham’s mission is to provide its clients with the long-term advice they need to achieve their business goals.

In additon, Cannacord Capital's team of over 50 research professionals are saying that shares of Allos will likely be priced to perfection this morning following the OCAC's endorsement of FOLOTYNTM and they are recommending that investors take their profits.

Cannacrod Capital is committed to maintaining integrity and an independent view, providing meaningful insight into the global capital markets.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus